Compare Becton Dickinson and Co (BDX) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs SOLAI Limited — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $49.41B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: Becton Dickinson and Co is far larger — about 2960.5× SOLAI Limited's market cap, and Becton Dickinson and Co pays a 2.32% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| BDX | SLAI | |
|---|---|---|
Market Cap | $49.41B | $16.69M |
Sector | Health | Technology |
52-Week High | $185.39 | $26.74 |
52-Week Low | $138.62 | $2.74 |
Enterprise Value | $65.51B | $16.33M |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $180.64, up 0.56% today, near its consensus price target of $183. The stock shows bullish technical signals with strong moving averages and recent earnings beats in Q2 2026. Revenue growth is steady, with Q3 2026 reaching $5 billion, though margins face pressure from tariffs. The company maintains a Dividend Aristocrat status with consistent payouts.
Outlook is cautiously optimistic with analyst consensus leaning buy, but risks include margin compression and debt levels. The stock offers stability through dividends and sector resilience, yet investors should monitor earnings sustainability and competitive threats in the medical technology space.
SLAI trades at $3.72 with no recent price change. The stock shows a bullish technical signal, but the company faces severe financial distress with negative gross and net income margins, and a net loss of $33.88 million in 2025. A reverse stock split was executed on July 6, 2026, and the NYSE has commenced delisting proceedings, creating significant uncertainty.
The outlook is highly speculative. The acquisition of a stake in NEURALAND and the launch of Solode Neo represent potential growth avenues, but the delisting risk and persistent losses overshadow any near-term upside. Investors face substantial risk of capital loss.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
